Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0029463 (osteosarcoma)
 16,637 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The concentrations of vascular endothelium growth factor and angiogenin were measured by enzyme immunoassay in the sera of healthy subjects and patients with osteosarcoma and Ewing's tumor with consideration for the main clinical and morphological characteristics of the diseases. The studied angiogenic factors were characterized by high individual variability in both healthy subjects and age- and sex-matched patients with primary bone sarcomas. The level of endothelial growth factor was higher in control women than in men. The highest concentration of endothelial growth factor was detected in male patients with Ewing's tumor. Possible involvement of vascular endothelium growth factor and angiogenin in the pathogenesis of osteosarcoma and Ewing's tumor is discussed.
 ...
PMID:Vascular endothelium growth factor and angiogenin in the serum of patients with osteosarcoma and Ewing's tumor. 1114 May 88

Angiogenesis factor of human osteosarcoma was partially purified and its biological features were studied. The active peptide with 8000 to 10,000 u molecular weight in the conditioned medium obtained from the cultivation of human osteosarcoma cells were partially purified by ultrafiltration, chromatography and dialysis. The angiogenic effects of the fractions were assessed by proliferation assay of human umbilical vein and pig aorta thoracic endothelial cells. The results showed that the chromatography fractions of 4 to 6 could significantly promote the proliferation of the endothelial cells. It was suggested that the human osteosarcoma cells could synthesize and secrete angiogenesis factor with a molecular weight of 8000 to 10,000 u.
 ...
PMID:Study on angiogenesis factor of human osteosarcoma. 1121 57

The paper considers data of the long-term studies of androgen metabolism, baseline serum levels of reproductive steroid hormones and their receptors in the tumor, in the blood concentrations of sex steroid-binding globulin and pituitary hormones, the expression of epidermal growth factor, its receptors and ligands, soluble Fas-antigen, vascular endothelial growth factor, angiogenin, and the content of calmodulin, cAMP in the osteosarcoma in 300 patients aged 14 to 56 years, which were made at the N. N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences. Analyzing the findings identified some lines in the study of new pathogenetic treatments for osteosarcoma, aimed at regulating androgen metabolism, correcting the cyclooxygenase pathway of arachidonic acid, the expression of receptors of epidermal growth factor and its ligands, the processes of neoangiogenesis in the tumor. A role of the above parameters in the pathogenesis of osteosarcoma is discussed.
 ...
PMID:[Osteosarcoma: biochemical and endocrinological studies as a basis for its pathogenetic treatments]. 1188 79

It is proven that angiogenesis and cartilage resorption processes involving vascular endothelial growth factor (VEGF) and its receptors play an important role in bone tissue regeneration and bone tumor development. A comparative analysis of VEGE VEGF-R1, VEGF-R2 and angiogenin content in blood serum of healthy persons, and patients with primary malignant, benign and borderline bone tumors was performed. 366 bone tumor patients aged 14-76 years were examined; 223 (60,9%) male and 143 (39,1%) -female. Control group included 48 practically healthy subjects aged 15-69 years; 25 (52,1%) male and 23 (47,9%) female. Serum VEGE VEGF-R1, VEGF-R2 and angiogenin concentrations measured using standard ELISA kits produced by "R&D Systems Inc. ", USA. It was shown that long-term treatment outcome (3-years overall survival) of typical osteosarcoma patients depended on tumor malignancy grade (determined by the criterion G). Baseline serum VEGF, its soluble receptors and angiogenin concentrations had no predictive value.
 ...
PMID:Angiogenic factors in blood serum of bone tumor patients. 2464 99